Endocrinology ·
Retatrutide tops semaglutide on A1C and weight in type 2 diabetes, Lilly says; FDA trims boxed warnings on three estradiol patches
Listen to this post
read by AI voices · all episodesTHE SHORT READ
Eli Lilly said retatrutide lowered A1C more than semaglutide 2 mg and more than doubled its weight loss in a phase 3 type 2 diabetes trial. The Food and Drug Administration removed breast cancer, cardiovascular and dementia statements from boxed warnings on three estradiol patches, and Vanda Pharmaceuticals reported phase 3 data on tradipitant for semaglutide-induced vomiting.
THE DETAILS
- Research Oct 28, 2026In topline, company-reported results from the phase 3, open-label TRANSCEND-T2D-2 trial of 1,298 adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor, retatrutide 9 mg and 12 mg each lowered A1C 2.2% from a mean baseline of 8.3%, versus 1.8% for semaglutide 2 mg (Ozempic) at 80 weeks, Eli Lilly said Oct. 28. Weight fell 19.5% and 20.9% versus 9.4% under the efficacy estimand. The primary end point was noninferiority of the 12 mg dose on A1C. Discontinuation for adverse events was 4.8% and 7.9% versus 2.7%.
- FDA Oct 30, 2026The Department of Health and Human Services (HHS) said Oct. 30 that the Food and Drug Administration approved labels for three estradiol transdermal patches from two applicants that drop risk statements on cardiovascular disease, breast cancer and probable dementia from the boxed warning. The action extends a labeling effort the FDA began in November 2025; 29 drug companies have submitted proposed labeling changes, HHS said. The release did not name the products.
- Research Oct 27, 2026In a phase 3, randomized, placebo-controlled trial in which participants received a single 1 mg semaglutide dose, vomiting occurred in 43.0% (61 of 142) with the oral NK-1 receptor antagonist tradipitant versus 58.5% (96 of 164) with placebo (P = .006), Vanda Pharmaceuticals said Oct. 27 in topline results. The key secondary end point of vomiting plus a worst nausea score of 3 or more occurred in 33.1% versus 50.6% (P = .002). Two further analyses were post hoc and exploratory.Sources: Vanda Pharmaceuticals, HCPLive
The weekly innovation roundup for endocrinology, published every Sunday for the week before; every item links to its sources. Latest endocrinology news · All specialties